Adam L. Boxer, MD, PhD

Phone: 415-476-0668
UCSF Box: 1207
Email: aboxer@memory.ucsf.edu
UCSF Profile

Project Sponsor Location(s) Topics Start End
Biomarker Optimization for Progranulin Trials (The BOPT Study) Alzheimer Drug Discovery Foundation United States Neurology and Mental Health
BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer's Disease Bristol-Myers Squibb Company United States Pharmacology and Drug Treatment, Neurology and Mental Health
Eye Movement Control in Normal Elderly and MCI NIH National Institute on Aging United States Noncommunicable and/or Chronic Disease, Dementia and Cognitive Impairment
An Open Label Dose Finding Study of Nimodipine for the Treatment of Frontotemporal Dementia Due to Progranulin Insufficiency From GRN Gene Mutations Bluefield Project to Cure Frontotemporal Dementia (FTD) United States Pharmacology and Drug Treatment
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TPI-287 in Patients with Mild to Moderate Alzheimer's Disease Archer Biosciences, Inc. United States Noncommunicable and/or Chronic Disease, Dementia and Cognitive Impairment
Four Repeat Tauopathy Neuroimaging Initiative NIH National Institute on Aging United States Dementia and Cognitive Impairment
Phase I Multiple Ascending Dose Trial of the MT Stabilizer TPI-287 for Alzheimer Disease (AD) Alzheimer's Association, Inc. United States Pharmacology and Drug Treatment, Dementia and Cognitive Impairment
Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer's Diseases Genentech, Inc. United States Dementia and Cognitive Impairment
Causes, treatment and prevention of corticobasal degeneration Karin & Sten Mortstedt CBD Solutions AB United States
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab(LY2062430) versus Placebo Eli Lilly and Company United States Pharmacology and Drug Treatment, Dementia and Cognitive Impairment
Extension of Phase II Studies ABE4869g and ABE4955g in Patients with Mild to Moderate Alzheimer Disease Genentech, Inc. United States Dementia and Cognitive Impairment